Koers BioRestorative Therapies, Inc. Other OTC
Aandelen
BRTX
US0906554086
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 60K 55,71K | Omzet 2025 * | 60K 55,71K | Marktkapitalisatie | 9,27 mln. 8,61 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -17 mln. -15,79 mln. | Nettowinst (verlies) 2025 * | -20 mln. -18,57 mln. | EV/omzet 2024 * | 155 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 155 x |
K/w-verhouding 2024 * |
-0,64
x | K/w-verhouding 2025 * |
-0,65
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 81,2% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Lance Alstodt
CEO | Chief Executive Officer | 53 | 01-10-18 |
Robert Kristal
DFI | Director of Finance/CFO | - | 04-11-21 |
Compliance Officer | 55 | 01-09-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Patrick Williams
BRD | Director/Board Member | 51 | 29-10-21 |
David Rosa
BRD | Director/Board Member | 59 | 29-10-21 |
Francisco Silva
CTO | Chief Tech/Sci/R&D Officer | 49 | 13-04-11 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+3,91% | 109 mld. | |
+10,87% | 105 mld. | |
+1,28% | 22,25 mld. | |
-13,14% | 22,09 mld. | |
-7,05% | 18,68 mld. | |
-38,36% | 17,58 mld. | |
-10,66% | 16,85 mld. | |
+3,75% | 13,76 mld. | |
+36,70% | 12,46 mld. |